Mesoporous silica- and silicon-based materials ... - Helda - Helsinki.fi

Gomez-Orellana, I., 2005. Strategies to improve oral drug bioavailability. Expert Opin. Drug
Deliv. 2, 419-433.
Gong, K., Viboonkiat, R., Rehman, I.U., Buckton, G., Darr, J.A., 2005. Formation and
characterization of porous indomethacin-PVP coprecipitates prepared using solvent-free
supercritical fluid processing. J. Pharm. Sci. 94, 2583-2590.
Greco, K., Bogner, R., 2010. Crystallization of amorphous indomethacin during dissolution: Effect
of processing and annealing. Mol. Pharmaceutics 7, 1406-1418.
Gupta, M.K., Goldman, D., Bogner, R.H., Tseng, Y.-C., 2001. Enhanced drug dissolution and bulk
properties of solid dispersions granulated with a surface adsorbent. Pharm. Dev. Technol. 6, 563-
572.
Halimaoui, A., Oules, C., Bomchil, G., Bsiesy, A., Gaspard, F., Herino, R., Ligeon, M., Muller, F.,
1991. Electroluminescence in the visible range during anodic oxidation of porous silicon films.
Appl. Phys. Lett. 59, 304.
Han, Y.-J., Stucky, G.D., Butler, A., 1999. Mesoporous silicate sequestration and release of
proteins. J. Am. Chem. Soc. 121, 9897-9898.
Hancock, B.C., Parks, M., 2000. What is the true solubility advantage for amorphous
pharmaceuticals? Pharm. Res. 17, 397-404.
He, Q., Zhang, J., Chen, F., Guo, L., Zhu, Z., Shi, J., 2010. An anti-ROS/hepatic fibrosis drug
delivery system based on salvianolic acid B loaded mesoporous silica nanoparticles. Biomaterials
31, 7785-7796.
He, Q., Zhang, Z., Gao, Y., Shi, J., Li, Y., 2009. Intracellular localization and cytotoxicity of
spherical mesoporous silica nano- and microparticles. Small 5, 2722-2729.
He, X., Pei, L., Tong, H.H.Y., Zheng, Y., 2011. Comparison of spray freeze drying and the solvent
evaporation method for preparing solid dispersions of baicalein with Pluronic F68 to improve
dissolution and oral bioavailability. AAPS PharmSciTech, 12, 104-113.
Heikkilä, T., Salonen, J., Tuura, J., Hamdy, M.S., Mul, G., Kumar, N., Salmi, T., Murzin, D.Y.,
Laitinen, L., Kaukonen, A.M., Hirvonen, J., Lehto, V.-P., 2007a. Mesoporous silica material
TUD-1 as a drug delivery system. Int. J. Pharm. 331, 133–138.
Heikkilä, T., Salonen, J., Tuura, J., Kumar, N., Salmi, T., Murzin, D.Y., Hamdy, M.S., Mul, G.,
Laitinen, L., Kaukonen, A.M., Hirvonen, J., Lehto, V.-P., 2007b. Evaluation of mesoporous
TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery. Drug
Delivery 14, 337-347.
Heikkilä, T., Santos, H.A., Kumar, N., Murzin, D.Y., Salonen, J., Laaksonen, T., Peltonen, L.,
Hirvonen, J., Lehto, V.P., 2010. Cytotoxicity study of ordered mesoporous silica MCM-41 and
SBA-15 microparticles on Caco-2 cells. Eur. J. Pharm. Biopharm. 74, 483-494.
Hench, L., West, J., 1990. The sol-gel process. Chem. Rev. 90, 33-72.
Hilgers, A.R., Conradi, R.A., Burton, P.S., 1990. Caco-2 cell monolayers as a model for drug
transport across the intestinal mucosa. Pharm. Res. 7, 902-910.
50